Journal
CURRENT PROTEIN & PEPTIDE SCIENCE
Volume 23, Issue 7, Pages 456-464Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389203723666220705152713
Keywords
MTA1; prostate cancer; metastasis; treatment; transcriptional regulation; modulator
Categories
Ask authors/readers for more resources
Prostate cancer is one of the most common cancers in the male genitourinary system, with a significant increase in morbidity and mortality in recent years. MTA1, a transcriptional coregulator, plays a crucial role in the formation, progression, and metastasis of PCa, making it a potential target for treatment.
Prostate cancer (PCa) is the most frequent cancer of the male genitourinary system and the second most common cancer in men worldwide. PCa has become one of the leading diseases endangering men's health in Asia in recent years, with a large increase in morbidity and mortality. MTA1 (metastasis-associated antigen-1), a transcriptional coregulator involved in histone deacetylation and nucleosome remodeling, is a member of the MTA family. MTA1 is involved in cell signaling, chromosomal remodeling, and transcriptional activities, all of which are important for epithelial cell progression, invasion, and growth. MTA1 has been demonstrated to play a significant role in the formation, progression, and metastasis of PCa, and MTA1 expression is specifically linked to PCa bone metastases. Therefore, MTA1 may be a potential target for PCa prevention and treatment. Here, we reviewed the structure, function, and expression of MTA1 in PCa as well as drugs that target MTA1 to highlight a potential new treatment for PCa.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available